Atacand Articles
AstraZeneca sees 17% 1st qtr pretax growth
3 May 2000
AstraZeneca full-year profits up 20% as new products come good
24 February 2000
FDA accepts AstraZeneca's Atacand HCT
23 December 1999
AstraZeneca unveils promising portfolio with 57 NCEs
14 December 1999
AstraZeneca's Atacand shows superiority over Merck's Cozaar
19 August 1999
SCOPE to look at cognition in elderly
12 April 1999
Takeda entering new phase of global expansion, says MSDW analyst
18 February 1999
Astra sees fourth qtr sales leap 46% and rise 27% for full-year 1998
16 February 1999
Beyond ACE inhibition: the future of angiotensin I inhibitors
11 February 1999
Candesartan trial shows benefits in women
4 February 1999
AstraZeneca's Effect On Rest Of Pharma Sector
17 December 1998
Telmisartan Becomes Sixth AIIRA To Be Registered
19 November 1998
"Underlying Quality" In Novartis' Growth
2 November 1998
Atacand In USA
22 October 1998
Takeda Pharma Sets Up Swiss Subsidiary
11 September 1998
CHARM Trial Of Candesartan
10 September 1998
Candesartan Approved In The USA
15 June 1998
GW Makes Foray Into Cardiovascular Arena
18 March 1998
Astra Remains Popular Stock With Analysts
19 February 1998
Takeda, Diabetes Drive Japanese Blockbusters
19 February 1998
Top Pharma & Biotech Stock Picks For 1998
4 February 1998
Highlights Of Astra's Pipeline Presentation
30 January 1998
Astra R&D Update Seeks To Allay Market Fears
23 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
Astra's Atacand Reaches First Market
26 November 1997
Candesartan CHF Trial Stopped On Mortality Concerns
24 November 1997
Candesartan Gets EU Approval
9 October 1997
First Market For Takeda's Candesartan Will Be UK
29 September 1997
Slow Growth Again For Astra In 2nd Qtr
12 August 1997
Shock Growth Slowdown At Sweden's Astra
23 April 1997
- Candesartan Cilexetil Submissions By Fall 1996
22 April 1996
Astra Strengthens R&D With Increased Spending
4 December 1995
Takeda Advancing Despite Challenging Environment
5 September 1994
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
